PRESS-RELEASE ·Filed Jun 17, 2026
Press release · FDA
Actionable Insight • Neutral
No material business updates. Monitor upcoming clinical trial milestones for SAT-3247 in Duchenne muscular dystrophy (DMD), including the BASECAMP and TRAILHEAD Phase II trials.
Final — all horizons settled through T+60d ⚠ clustered
MSLE ▲ +71.45% at T+60d
NEUTRAL call +71.45% · α vs SPY +69.56% · entry $5.71 → $9.79
T+1d
+1.40%
call +1.40% · α +1.72%
$5.79
settled 4mo ago
T+5d
+17.51%
call +17.51% · α +19.18%
$6.71
settled 4mo ago
T+20d
+53.42%
call +53.42% · α +52.88%
$8.76
settled 3mo ago
T+60d
+71.45%
call +71.45% · α +69.56%
$9.79
settled 6w ago
Price Chart
Loading chart...
Executive Summary
Satellos Bioscience Inc. held its Annual Meeting of Shareholders on June 17, 2026, with all director nominees elected and PricewaterhouseCoopers LLP reappointed as auditors. The results are routine corporate governance items with no material financial impact.
Key Facts
- All nine director nominees were elected with majority support; Stephanie Brown received 92.22% for and 7.78% against, Iris Loew-Friedrich received 83.76% for and 16.24% against.
- PricewaterhouseCoopers LLP was reappointed as auditors.
- Approximately 55.3% of outstanding shares were represented at the meeting.
Financial Impact
No financial impact from the shareholder meeting results.
Risk Factors
- Clinical trial risks for SAT-3247 (Phase II data readouts, safety/efficacy).
- Notable shareholder dissent for two directors (16.24% and 7.78% against) may indicate governance concerns.
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (10 analysts)
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3313837 |
22 reports for MSLE
71% Hit rate @ T+20 Went positive at some point 5 of 8 best @ T+20▲ +23.95%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $6.42 | awaiting T+20 | — | $6.88 (+7.17%) |
Oct 21, 2026 6d ago | 6-K | $6.70 | awaiting T+20 | — | $6.88 (+2.69%) |
Oct 5, 2026 22d ago | 6-K | $8.05 | awaiting T+20 | — | $6.88 (−14.53%) |
Sep 30, 2026 27d ago | 6-K | $8.50 | awaiting T+20 | — | $6.88 (−19.06%) |
Sep 30, 2026 27d ago | Press Release | $8.50 | awaiting T+20 | — | $6.88 (−19.06%) |
Sep 24, 2026 4w ago | 6-K | $8.71 $6.63 | ▼ −23.94% | ▼ −23.52% | $6.88 (−21.01%) |
Sep 24, 2026 4w ago | Press Release | $8.71 $6.63 | ▼ −23.94% | ▼ −23.52% | $6.88 (−21.01%) |
Sep 15, 2026 6w ago | 6-K | $9.36 $7.04 | ▼ −24.79% | ▼ −27.51% | $6.88 (−26.50%) |
Sep 9, 2026 6w ago | 6-K | $10.02 $7.63 | ▼ −23.85% | ▼ −26.05% | $6.88 (−31.34%) |
Sep 1, 2026 8w ago | 6-K | $9.08 $8.69 | ▼ −4.30% | ▼ −5.48% | $6.88 (−24.23%) |
Showing 10 of 22
US Market Status
Market Closed — Opens Thu (10h 2m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers